Featured Articles

Features

Global chemistry, manufacturing, and controls (CMC) postapproval changes (PACs) are still managed largely through fragmented, country-by-country processes that duplicate sponsor and regulator effort, increase cost, prolong implementation timelines, add supply chain complexity, discourage continual improvement, and delay patient-centric enhancements.

Features

ICH Q12’s intent is to enable a holistic control strategy and provide regulatory tools for continual improvement over the product life cycle, thereby promoting innovation. However, slow implementation of ICH Q12 tools by regulatory agencies has created challenges for industry to fully use Q12 concepts in regulatory submissions.

Technical

Bioreactor contamination can be one of the most troublesome and costly deviations to resolve in a GMP manufacturing facility. That’s both because cell culture unit operations are inherently susceptible to contamination and because tracking down the source of contamination can be extremely difficult.

Technical

Physical temperature buffers function as low-pass filters on the thermal environment of pharmaceutical storage units and are widely used to dampen transient fluctuations and mimic product thermal behavior. This article presents a study that quantifies the limitations of fixed physical buffering and evaluates model-based buffering’s ability to address those limitations.

Features

Quality professionals in all industries are heavily involved in root-cause analysis (RCA) and corrective and preventive action (CAPA) management. As artificial intelligence (AI) systems emerge to augment these quality functions, the industry faces a fundamental challenge: no comprehensive regulatory framework exists to govern AI application in GxP environments.

Features

By adopting artificial intelligence (AI) and machine learning (ML), the life sciences industry can leverage dynamic systems, a completely new system design. These systems feature ML models that learn adaptively automatically from data, accommodating changing relationships between input and output over time.

Features

Cell and gene therapies (C&GTs) offer a groundbreaking approach for disease treatment by targeting conditions at the cellular and genetic level, offering hope for previously untreatable disorders. As these therapies progress from clinical trials to commercial reality, manufacturing challenges—particularly the need for robust, scalable, and cost-effective production—remain a significant...

Features

Mold contamination is one of the most persistent threats to cleanroom integrity in pharmaceutical manufacturing. This article highlights the sources, growth conditions, and pathways for mold ingress. It emphasizes the need for an integrated approach combining facility design, environmental monitoring, effective investigation, and robust cleaning and sanitization programs.

Technical

This article presents experiences from seven recent accelerated development program case studies. These experiences provide insights that could help companies progressing through accelerated development programs for products meeting unmet medical needs or significant therapeutic needs, such as those with anticipated Breakthrough Therapy (United States) or PRIME (European Union) designation.

Technical

This article examines the regulatory landscape governing artificial intelligence (AI) in quality-critical systems and distinguishes between algorithms, AI, and a nuanced middle category called smart systems. It explains how organizations can responsibly embrace advanced programmatic solutions while preserving the integrity of validated test methods and safeguarding patient safety.

Technical

Shelf temperature mapping is a critical component of lyophilizer qualification. The previous articles in this series explored the methods used to record the shelf surface temperatures (Part I) and designing an appropriate study (Part II). Interpreting a shelf temperature mapping study’s result is as critical to assessing uniformity as the temperature measurement, the study design, and the...

Technical

The promise of single-use technologies (SUTs) in biopharmaceutical manufacturing is as compelling as it is contradictory. Noted for accelerating process development, enhancing sterility, and enabling unprecedented manufacturing agility, SUTs have also introduced a less visible but mounting challenge: the steady accumulation of complex plastic waste.

Technical

Bulk powders inherently exhibit unpredictable flow in feeders, dosing machines, and packed machines under gravity's pull. Meanwhile, particle engineering co-processed excipients can be more versatile and economical compared to conventional ingredients in the continuous manufacturing of drug products.

Features

In today’s pharmaceutical landscape, speed, compliance, and efficiency are no longer optional—they’re strategic imperatives. Yet for large capital expenditure (CapEx) projects, traditional paper-based commissioning, qualification, and validation (CQV) workflows remain a major bottleneck, consuming time, resources, and patience.

Features
The pharmaceutical industry is at a pivotal moment. The pressure to deliver safe, high-quality medicines to patients faster has never been greater, and the systems used to ensure compliance must evolve to meet that challenge. Commissioning and qualification (C&Q), long the bedrock of pharmaceutical engineering and compliance are being reshaped by new science- and risk-based approaches that...
Features

Radiopharmaceuticals account for many lifesaving diagnostic and therapeutic drug products in the market. These drug products, radioligand therapies (RLTs) in particular, represent a relatively novel modality and present multiple, unique challenges to manufacture, release, ship, and administer.

Features

ASTM E2500, issued in 2007, has been the primary standard guide defining what is required to apply quality risk management (QRM) to achieve the qualification of facilities, systems, and equipment in support of validation and process validation. A major update was undertaken in 2024 to better align the guide with current regulatory and industry guidance and current best practice.

Features

Schedule management faces challenges such as unrealistic deadlines, scope creep, resource constraints, and poor communication, often causing delays and cost overruns. Using tools like an interdependency matrix (IDM) with project management software tools like Microsoft Project improves accuracy, visibility, and control.

Features

This article provides guidance on the best practices to adopt when preparing for an audit or inspection, with a particular focus on commissioning and qualification and the points to consider during the development of materials to explain a company’s individual approach to commissioning, qualification, and validation maintenance.

Features
Computerized system validation (CSV) remains a cornerstone of regulatory compliance, but it is still time-consuming, resource-intensive, and prone to human error. Risk assessments, test development, traceability, and documentation absorb enormous effort and often slow down innovation. Artificial intelligence (AI) has the potential to change this.
Features

Categorization offers a useful starting point for assessing the risk of failure for individual software components, but it is not a validation checklist. Organizations must apply critical thinking to combine categorization with risk assessment and supplier assessments to appropriately scale life cycle activities and manage risk.

Explore

White Paper
This whitepaper provides principles and practical expectations for manufacturing operations within the scope of GMP Annex 1, focusing on four areas: environmental monitoring and control; aseptic process validation; equipment and facility design; and personnel practices. Each subject area was drafted as an individual chapter to the whitepaper by multicompany and multidisciplinary teams with...
White Paper
The life science validation sector is evolving with a focus on risk-based methodologies and increased access to digital data, driving innovation. The rise of Digital Validation Tools (DVTs) reflects the industry's emphasis on data integrity and principles of Pharma 4.0 and Validation 4.0. These advancements streamline monitoring and provide real-time insights into validated statuses through...
White Paper

Currently, there is no single guidance document providing a comprehensive roadmap for executing digital validation. While elements from ISPE GAMP® Guides Series and the ISPE Baseline® Guide: Volume 8 – Pharma 4.0™, apply to digital validation, there is no consolidated resource addressing common questions. The authors of this Concept Paper therefore advocate for the development of a Good...

Latest Articles

iSpeak Blog

The pharmaceutical industry has operated historically through localized and siloed approaches, where individual facilities developed independent procedures, design philosophies and operational practices. While such autonomy offered flexibility and responsiveness to site specific requirements, it has also introduced significant challenges, including duplication of efforts, inconsistency,...

iSpeak Blog

Artificial Intelligence (AI) and machine learning (ML) are reshaping how pharmaceutical organizations understand, develop, manufacture, and control medicinal products. Their potential extends beyond process optimization: AI-derived insights can strengthen pharmaceutical chemistry, manufacturing, and controls (CMC), support process validation, improve quality risk management, and enhance...

iSpeak Blog

Building on the establishment of the ISPE Netherlands Quality Community of Practice (CoP) in 2025, this article reflects on its official launch event, held on 9 June 2026 at the Biotech Training Facility, located in Leiden Bio Science Park in Leiden, the Netherlands. Bringing together more than 50 pharmaceutical professionals, the event explored how quality can evolve beyond traditional...

iSpeak Blog
In a recent episode of ISPE Podcast: Shaping the Future of Pharma[KL4.1], CaiXue Wei, Vice President of Manufacturing and Operations, Global Industrial Affairs at Hepalink, shared how the category award-winning facility was designed to address multiple manufacturing challenges simultaneously, from capacity constraints and sterility assurance to digital coordination and global supply resilience.
iSpeak Blog

For many community college students eyeing a career in the Bay Area’s thriving biotech scene, jumping from the classroom to a first job can feel like a huge leap. With so many career paths out there, it’s tough to know where to start. While bigger four-year universities may have their own industry networking programs, junior colleges often get left out of the picture. That’s where Brunch with...

iSpeak Blog

As pharmaceutical manufacturing facilities grow increasingly digitized and data-rich, the quality of operational decisions depends not on the volume of data collected, but on how well that information is contextualized and shared. Intelligent visual operational systems, which combines human-centered interface design with contextualized, AI-assisted decision support, can fundamentally...

iSpeak Blog

Two firms assessed much the same system in the same month. Both had bought a model that flags chromatograms for analyst review. The first firm treated it as high risk, and it is understandable why: AI, laboratory data, and batch decisions somewhere downstream. They budgeted six months of validation, wrote scripted tests against every function, and built a monitoring program fit for a system...

iSpeak Blog
The pharmaceutical industry is increasingly looking to Artificial intelligence (AI) as a potential solution to some of manufacturing’s most persistent challenges. Organizations are exploring how AI can reduce the effort required to create and review documents, improve right-first-time performance, standardize investigations and other quality processes, accelerate access to knowledge, support...
iSpeak Blog

As reindustrialization accelerates, new facilities are being built—not as replicas of the past but as digitally native, intelligent environments. These modern factories are designed to bridge the long-standing divide between the information technology (IT) world and the physical world, enabling smarter, faster and more resilient operations.

iSpeak Blog

Commercial oligonucleotide therapeutics are emerging at an unprecedented pace. Many of these products employ novel mechanisms of action, often targeting RNA directly rather than proteins, representing a significant shift in therapeutic strategy. This growth is expected to continue as oligonucleotide technologies expand into larger patient populations and new indications.

iSpeak Blog

As pharmaceutical and biopharmaceutical manufacturers face increasing global competition, rising operational costs, and growing regulatory complexity, the need for smarter, more integrated manufacturing strategies has never been greater. Organizations are under pressure to improve efficiency and throughput while maintaining the robust quality systems and operational reliability required in...

iSpeak Blog
Every major transformation in life sciences has been built upon the foundations established by the one before it. The digitization of regulatory dossiers and enterprise documents created accessibility and transparency. The shift toward structured digital records enabled workflow automation, improved compliance, and data-driven decision-making. Now, the emergence of artificial intelligence (AI) is...
iSpeak Blog

The development and deployment of mRNA COVID-19 vaccines accelerated interest in RNA as a therapeutic platform. RNA-based approaches are now being investigated or developed for applications including vaccines, cancer immunotherapies, protein replacement, and gene editing.

iSpeak Blog

The pharmaceutical industry is entering an unprecedented era of capital investment, with major programs underway to expand manufacturing capacity, modernize facilities, strengthen supply-chain resilience and accelerate the adoption of next-generation technologies. Yet as investment increases, critical question is emerging: does the industry have sufficient execution capability to deliver these...

iSpeak Blog

The pharmaceutical industry has spent years exploring the possibilities of digital transformation. Today, however, the conversation has shifted. The challenge is no longer identifying promising technologies. Instead, manufacturers are focused on scaling automation, artificial intelligence (AI), advanced analytics, and digital systems across global operations while maintaining quality,...

iSpeak Blog
What happens when a pharmaceutical manufacturer rethinks nearly every aspect of traditional oral solid dosage production? Bayer AG's award-winning SOLIDA-1 facility offers one answer. Designed around modularity, autonomous operations, and integrated digital technologies, the facility demonstrates how manufacturers can increase flexibility, improve efficiency, and prepare for future industry needs.
iSpeak Blog

Scientific innovation continues to accelerate across the pharmaceutical and biopharmaceutical industries. From biologics and antibody-drug conjugates to cell and gene therapies, mRNA technologies, and radiopharmaceuticals, new treatment modalities are creating opportunities to address some of the world's most challenging diseases. Yet scientific discovery is only part of the journey. Ensuring...

Current Issue

September / October 2026

This issue examines the intersection of quality and regulatory innovation, tracing the evolution of Quality Management from defect detection to continuous improvement and operational excellence. It aims to provide practical insights into advancing quality, efficiency, and regulatory flexibility across the pharmaceutical industry.